Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium GlobeNewswire Sep 25, 2024 12:00pm
Erasca Reports Second Quarter 2024 Business Updates and Financial Results GlobeNewswire Aug 12, 2024 8:01pm